Cellectis S.A. (CLLS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Cellectis S.A. (CLLS) closed at USD 1.12 on 2026-10-14, a change of -68.7 % over the past year, with a market capitalization of USD 111.31M.

Cellectis S.A. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Cellectis S.A. key figures

Previous close

USD 1.12 (2026-10-14)

1-year change

-68.7 %

Market cap

USD 111.31M

Enterprise value

USD -6M

P/E ratio (trailing)

-1.73

P/E ratio (forward)

-1.78

EPS (trailing)

-0.64

EPS (forward)

-0.62

PEG ratio

n/a

Price to book

1.96

Revenue growth

-62.1 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.91

Employees

224

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Cellectis S.A.

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Cellectis S.A. and compare it with other stocks.